View Clinical Trial (Medical Research Study)

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms - NCT01052103-20016(Clinical Trial 478924)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Washington
State:  
DC
Zip Code: 20016
Conditions: Schizophrenia
Purpose: The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.
Study summary:
Criteria: Inclusion Criteria: - Clinical diagnosis of schizophrenia - Patients must have been receiving monotherapy treatment for at least 3 months prior to study entry with one of 4 atypical antipsychotic medications (aripiprazole, olanzapine, risperidone, quetiapine) - Disease symptoms must meet a certain range as assessed by the clinician - Patients must have evidence of prominent negative symptoms of schizophrenia (i.e. blunted affect, emotional withdrawal, or motor retardation) - Patients must be considered reliable, have a level of understanding sufficient to perform all tests and examinations required by the protocol, and be willing to perform all study procedures - Patients must be able to understand the nature of the study and have given their informed consent Exclusion Criteria: - Patients who are actively suicidal - Patients who are pregnant or nursing - Patients who have had electroconvulsive therapy (ECT) within 3 months of screening or who will have ECT at any time during the study - Patients with uncorrected narrow-angle glaucoma, history of or current seizure disorder, uncontrolled diabetes, certain diseases of the liver, renal insufficiency, uncontrolled thyroid condition or other serious or unstable illnesses - Patients with Parkinson's disease, psychosis related to dementia or related disorders - Patients with known Human Immunodeficiency Virus positive (HIV+) status
Study is available at: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Washington, DC 20016
United States

Primary Contact:
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Phone: 1-317-615-4559
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.